Quantcast

Latest Avanir Pharmaceuticals Inc. Stories

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...

2014-06-30 20:22:37

ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela...

2014-06-24 08:31:20

ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM) Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56(th) Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel...

2014-06-10 04:22:17

--Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment-- ALISO VIEJO, Calif., June 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary...

2014-05-30 08:25:39

ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul -- Burden of...

2014-05-28 08:33:05

ALISO VIEJO, Calif., May 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in June. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO -- Jefferies 2014 Global Healthcare Conference -- Presentation date: Tuesday, June 3, 2014 -- Presentation time: 3:30 p.m. E.T. -- The JMP Securities Healthcare Conference -- Presentation...

2014-05-27 08:29:52

ALISO VIEJO, Calif., May 27, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO "Final completion of enrollment in this study is an important milestone for...

2014-05-06 16:32:33

ALISO VIEJO, Calif., May 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Quarterly Financial Highlights -- Total company net revenues of $26.9 million -- Net NUEDEXTA® sales of $24.4 million -- Cash, cash equivalents, and restricted investments of $56.5 million as of March 31, 2014. "We are extremely pleased...

2014-05-01 16:31:27

ALISO VIEJO, Calif., May 1, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in May. -- Deutsche Bank 39th Annual Health Care Conference -- Presentation date: Thursday, May 8, 2014 -- Presentation time: 2:10 p.m. E.T. -- Bank of America Merrill Lynch 2014 Health Care Conference -- Presentation date: Tuesday, May 13, 2014...

2014-04-30 16:30:05

ALISO VIEJO, Calif., April 30, 2014, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs') for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related